Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > Fc epsilon RI alpha > EP-169

Fc epsilon RI alpha [Biotinylated] : IgE Fc Inhibitor Screening ELISA Kit

For research use only.

Order Now

    Materials Provided
    IDComponentsSize
    EP169-C01High-bind Plate1 plate
    EP169-C02Human IgE Fc60 μg
    EP169-C03Human Fc epsilon RI alpha-SABC0.583 μg
    EP169-C04Anti-IgE (Omalizumab) 30 μg
    EP169-C05Coating Buffer12 mL
    EP169-C0620×Washing Buffer 50 mL
    EP169-C07Blocking Buffer50 mL
    EP169-C08Substrate Solution12 mL
    EP169-C09Stop Solution7 mL
  • Application

    This kit is developed for screening for inhibitors of human IgE Fc binding to human Fc epsilon RI alpha.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    1. Unopened kit should be stored at 2℃-8℃ upon receiving.

    2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A) is also known as Fc-epsilon RI-alpha (FcERI), IgE Fc receptor subunit alpha, FCE1A. FCER1A contains two Ig-like (immunoglobulin-like) domains. FCER1A binds to the Fc region of immunoglobulins epsilon and is a high affinity receptor. FCER1A is responsible for initiating the allergic response, which binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines. FCER1A plays a central role in allergic disease, coupling allergen and mast cell to initiate the inflammatory and immediate hypersensitivity responses that are characteristic of disorders such as hay fever and asthma.

    Your experiment will include 4 simple steps:

    1) Coat the plate with Human IgE Fc.

    2) Add your molecule of interest to the tests.

    3) Add Human Fc epsilon RI alpha-SABC to bind the coated Human IgE Fc.

    4) Add TMB or other colorimetric HRP substrate.

    Finally, the ability of your compound to inhibit IgE Fc : Fc epsilon RI alpha binding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to DS document for the assay protocol.
 Fc epsilon RI alpha TYPICAL DATA

Serial dilutions of Anti-IgE (Omalizumab) (Catalog # EP169-C04) (1:1 serial dilution, from 5μg/mL to 0.078125μg/mL) was added into Human IgE Fc: Biotinylated Human Fc epsilon RI alpha binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
For each experiment, a standard curve needs to be set for each micro-plate, and the specific OD value may vary depending on different laboratories, testers, or equipments. The example data is for reference only.

  • Background: Fc epsilon RI alpha
    High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A) is also known as Fc-epsilon RI-alpha (FcERI), IgE Fc receptor subunit alpha, FCE1A. FCER1A contains two Ig-like (immunoglobulin-like) domains. FCER1A binds to the Fc region of immunoglobulins epsilon and is a high affinity receptor. FCER1A is responsible for initiating the allergic response, which binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines. FCER1A plays a central role in allergic disease, coupling allergen and mast cell to initiate the inflammatory and immediate hypersensitivity responses that are characteristic of disorders such as hay fever and asthma.
  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:0 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message